갑상선 질환 치료제 시장 : 약물 유형별, 질환별, 투여 경로별, 유통 채널별 - 세계 예측(2024-2032년)

Thyroid gland disorder treatment market size is expected to register 3.9% CAGR between 2024 to 2032, driven by the increasing prevalence of thyroid disorders worldwide including hypothyroidism, hyperthyroidism, and thyroid cancer. As per Lancet, thyroid diseases impact approximately 200 million individuals globally. Factors, such as iodine deficiency, autoimmune diseases, genetic predisposition, and lifestyle changes are contributing to the high incidence of thyroid diseases especially in the elderly population. With the increasing thyroid health awareness and improving diagnostic capabilities, more individuals are seeking medical help.

Advancements in medical technology and treatment are driving innovations in the management of thyroid diseases. New therapeutic approaches, including targeted therapy, radioiodine therapy, minimally invasive surgical techniques, and precision medicine are providing more appropriate and effective treatment for patients. The development of new diagnostic tools and biomarkers is also enabling the earlier diagnosis and monitoring of thyroid disease while facilitating timely intervention and improving patient outcomes.

The thyroid gland disorder treatment industry is divided into drug type, disease, route of administration, distribution channel, and region.

Based on drug type, the market size from the beta blocker segment is projected to observe substantial CAGR through 2032 as it is effective in managing the symptoms associated with hyperthyroidism. Beta-blockers, such as propranolol and atenolol help in relieving symptoms like heart palpitations, tremors, and anxiety by blocking the effects of excess thyroid hormone on the cardiovascular system. These drugs also provide symptom relief, when the root cause of hyperthyroidism is addressed, either through medication, radioactive iodine therapy, or surgery.

Thyroid gland disorder treatment industry from the hyperthyroidism disease segment is anticipated to record significant growth rate during 2024- 2032 due to the increasing prevalence of this condition worldwide. Hyperthyroidism, characterized by overactive thyroid glands, can cause symptoms including rapid heartbeat, weight loss and anxiety, while significantly affecting the quality of life of patients. Medical interventions for hyperthyroidism, including medication, radioactive iodine therapy and surgery, have also grown necessary to manage symptoms, normalize thyroid hormone levels and prevent complications.

Asia Pacific thyroid gland disorder treatment industry is predicted to grow at a decent rate through 2032, attributed to the rapidly expanding healthcare infrastructure and the increasing access to medical services. The strong prevalence of thyroid disease in the region due iodine deficiency, changing lifestyles and increasing awareness is contributing to the high demand for treatment of hypothyroidism, stimulating the regional market expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of thyroid disorders
    • 3.2.1.2 Technological advancements in drug formulations
    • 3.2.1.3 Increasing healthcare expenditure
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects and complications of treatment
    • 3.2.2.2 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Levothyroxine
• 5.3 Liothyronine
• 5.4 Propylthiouracil
• 5.5 Imidazole-based compounds
• 5.6 Beta-blockers
• 5.7 Other drug types

Chapter 6 Market Estimates and Forecast, By Disease, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hypothyroidism
• 6.3 Hyperthyroidism

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Intravenous
• 7.4 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Wholesalers/distributors
• 8.3 Retail chain
• 8.4 Online distribution
• 8.5 Other distribution channels

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 AbbVie Inc.
• 10.3 Aspen Pharmacare Holdings Limited
• 10.4 Glenmark Pharmaceuticals Ltd.
• 10.5 Lannett Company, Inc.
• 10.6 Merck & Co., Inc.
• 10.7 Mylan N.V.
• 10.8 Novartis AG
• 10.9 Pfizer Inc.
• 10.10 Sun Pharmaceutical Industries Limited